Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iladatuzumab vedotin in R/R B-cell NHL
NCT02453087Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Primary completion
- Jul 2019
- Modality
- Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of iladatuzumab vedotin in B-cell non-Hodgkin lymphoma (B-NHL) (3 arms), sponsored by Roche. Primary endpoints: Number of Participants with Adverse Events up to 1 year, Percentage of Participants with Dose-Limiting Toxicities and 2 more. Started Aug 2015; status: completed.
02
Drugs
iladatuzumab vedotin
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT02453087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453087.